These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19708980)

  • 1. Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit.
    Perna AF; Ingrosso D; Violetti E; Luciano MG; Sepe I; Lanza D; Capasso R; Ascione E; Raiola I; Lombardi C; Stenvinkel P; Massy Z; De Santo NG
    Semin Dial; 2009; 22(4):351-6. PubMed ID: 19708980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in hyperhomocysteinemic states. A special focus on uremia.
    Ingrosso D; Perna AF
    Biochim Biophys Acta; 2009 Sep; 1790(9):892-9. PubMed ID: 19245874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is homocysteine toxic in uremia?
    Perna AF; Luciano MG; Pulzella P; Satta E; Capasso R; Lombardi C; Ingrosso D; De Santo NG
    J Ren Nutr; 2008 Jan; 18(1):12-7. PubMed ID: 18089438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The methionine-homocysteine cycle and its effects on cognitive diseases.
    Miller AL
    Altern Med Rev; 2003 Feb; 8(1):7-19. PubMed ID: 12611557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin.
    Perna AF; Castaldo P; Ingrosso D; De Santo NG
    J Nephrol; 1999; 12(4):230-40. PubMed ID: 10493566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
    J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine in uremia.
    Perna AF; Ingrosso D; Lombardi C; Cesare CM; Acantora F; Satta E; De Santo NG
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S123-6. PubMed ID: 12612968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
    Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
    Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Homocysteine. The cardiovascular risk factor of the next millennium?].
    Suárez García I; Gómez Cerezo JF; Ríos Blanco JJ; Barbado Hernández FJ; Vázquez Rodríguez JJ
    An Med Interna; 2001 Apr; 18(4):211-7. PubMed ID: 11496543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism.
    De Caterina R; Zampolli A; Madonna R; Fioretti P; Vanuzzo D
    Ital Heart J; 2004 Jun; 5 Suppl 6():19S-24S. PubMed ID: 15185912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Homocysteine and hyperhomocysteinemia].
    Laskowska-Klita T
    Pol Merkur Lekarski; 2001 Mar; 10(57):135-7. PubMed ID: 11398509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
    Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
    Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis.
    Hoţoleanu C; Porojan-Iuga M; Rusu ML; Andercou A
    Rom J Intern Med; 2007; 45(2):159-64. PubMed ID: 18333369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.
    Booth GL; Wang EE
    CMAJ; 2000 Jul; 163(1):21-9. PubMed ID: 10920726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Homocysteine metabolism and risk of cardiovascular diseases: importance of the nutritional status on folic acid, vitamins B6 and B12].
    Alemán G; Tovar AR; Torres N
    Rev Invest Clin; 2001; 53(2):141-51. PubMed ID: 11421110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences.
    Perna AF; Capasso R; Acanfora F; Satta E; Lombardi C; Ingrosso D; Violetti E; Romano MM; De Santo NG
    Semin Nephrol; 2006 Jan; 26(1):20-3. PubMed ID: 16412820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Consequences of moderate hyperhomocysteinemia in internal medicine].
    Zák A; Zeman M
    Cas Lek Cesk; 2004; 143(6):367-74. PubMed ID: 15309862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
    Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
    Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.